Cargando…
P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL
Autores principales: | Jain, N., Roboz, G., Konopleva, M., Liu, H., Schiller, G., Jabbour, E., Desai, P., Whitfield, D., Haider, A., Zernovak, O., Frattini, M., Brownstein, C., Larson, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429740/ http://dx.doi.org/10.1097/01.HS9.0000848660.69944.40 |
Ejemplares similares
-
P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
por: Boissel, Nicolas, et al.
Publicado: (2023) -
Balli and dramatic madrigals
por: Monteverdi, Claudio, 1567-1643
Publicado: (1991) -
miR-22 in tumorigenesis
por: Song, Su Jung, et al.
Publicado: (2014) -
P1420: PRE-CLINICAL PROOF OF CONCEPT DEMONSTRATES ROBUST ACTIVITY OF UCART20X22 DUAL CAR T-CELLS FOR THE TREATMENT OF B-CELL MALIGNANCIES
por: Aranda Orgilles, B., et al.
Publicado: (2022) -
Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies
por: Zheng, Sisi, et al.
Publicado: (2022)